A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study

被引：0
|
作者：
Xin Tang
Yuan Li
Wen-lei Qian
Wei-feng Yan
Tong Pang
You-ling Gong
Zhi-gang Yang
机构：
[1] West China Hospital,Department of Radiology
[2] Sichuan University,Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center
[3] West China Hospital,undefined
[4] Sichuan University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
Osimertinib; EGFR-T790M; Non-small cell lung cancer; Prognostic analysis; Real-world study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：2475 / 2486
页数：11
相关论文
共 50 条
  • [21] The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
    Pan, Guoqiang
    Chen, Kaiyan
    Yu, Xiaoqing
    Sheng, Jiamin
    Fan, Yun
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (06) : 2895 - 2905
  • [22] Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.
    Luo, Yung-Hung
    Liu, Han
    Wampfler, Jason A.
    Tazelaar, Henry D.
    Li, Yalun
    Peikert, Tobias
    Liu, Dan
    Leventakos, Konstantinos
    Chen, Yuh-Min
    Yang, Yanan
    Chiou, Shih-Hwa
    Yang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [24] The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
    Tang, X.
    Qian, W-L.
    Pang, T.
    Gong, Y-L.
    Yang, Z-G.
    ANNALS OF ONCOLOGY, 2021, 32 : S972 - S972
  • [25] A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
    Tan, Lavinia
    Brown, Chris
    Mersiades, Antony
    Lee, Chee Khoon
    John, Thomas
    Kao, Steven
    Newnham, Genni
    O'Byrne, Kenneth
    Parakh, Sagun
    Bray, Victoria
    Jasas, Kevin
    Yip, Sonia
    Wong, Stephen Q.
    Ftouni, Sarah
    Guinto, Jerick
    Chandrashekar, Sushma
    Clarke, Stephen
    Pavlakis, Nick
    Stockler, Martin R.
    Dawson, Sarah-Jane
    Solomon, Benjamin J.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [26] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhang, H. -L.
    Jiang, L. -Y.
    Shi, Y. -K.
    Chen, Y.
    Yu, J. -M.
    Zhou, C. -C.
    He, Y.
    Hu, Y. -P.
    Liang, Z. -A.
    Pan, Y. -Y.
    Zhuo, W. -L.
    Song, Y.
    Wu, G.
    Chen, G. -Y.
    Lu, Y.
    Zhang, C. -Y.
    Zhang, C. -Y.
    Zhang, Y. -P.
    Chen, Y.
    Lu, S.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
  • [27] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [28] Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
    Park, Sehhoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Sun, Jong-Mu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (09) : 1912 - +
  • [29] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) European subset
    Tiseo, M.
    Santo, A.
    Hochmair, M. J.
    Geldart, T.
    Metro, G.
    Hanrahan, E.
    Lamberg, K.
    Moran, T.
    Nyhus, C.
    Paredes, A.
    Vansteenkiste, J. F.
    Vicente, D.
    Miranda, M.
    Rigas, J.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer
    Lee, Jang Ho
    Kim, Eun Young
    Park, Cheol-Kyu
    Lee, Shin Yup
    Lee, Min Ki
    Yoon, Seong-Hoon
    Lee, Jeong Eun
    Lee, Sang Hoon
    Kim, Seung Joon
    Lee, Sung Yong
    Lim, Jun Hyeok
    Jang, Tae -Won
    Jang, Seung Hun
    Lee, Kye Young
    Lee, Seung Hyeun
    Yang, Sei Hoon
    Park, Dong Won
    Park, Chan Kwon
    Kang, Hye Seon
    Yeo, Chang Dong
    Choi, Chang-Min
    Lee, Jae Cheol
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 112 - 122
12345